Comparative Pharmacology
Head-to-head clinical analysis: AMIPAQUE versus FERIDEX I V.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIPAQUE versus FERIDEX I V.
AMIPAQUE vs FERIDEX I.V.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metrizamide, a non-ionic iodinated contrast agent, attenuates X-rays due to iodine content, enhancing radiographic imaging. It distributes in extracellular fluid and does not cross intact blood-brain barrier; in subarachnoid space, it outlines neural structures.
FERIDEX I.V. (ferumoxytol) is an iron oxide nanoparticle coated with a carbohydrate shell. After intravenous administration, ferumoxytol is taken up by macrophages of the reticuloendothelial system, releasing iron into the intracellular iron pool. Iron is transported by transferrin to erythroid precursor cells for hemoglobin synthesis, thereby replenishing iron stores.
200-300 mg iodine/kg body weight intravenously, maximum 60 g iodine per administration.
15 mg/kg intravenous infusion over 4 hours, maximum single dose 1200 mg, repeat after 72 hours if ferritin <100 ng/mL and transferrin saturation <20%.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment (up to 20-30 hours in severe renal failure).
Terminal elimination half-life (t½) of ferric carboxymaltose is approximately 7-12 hours (mean ~9 hours) in iron-deficient patients. Clinical context: The iron is rapidly delivered to the reticuloendothelial system for processing; reticulocyte response is seen within 1-2 weeks. The half-life reflects clearance of the complex from plasma, not iron turnover.
Primarily renal excretion via glomerular filtration; approximately 90-95% of the dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary route.
Primarily eliminated via hepatobiliary and fecal routes as intact complex; renal excretion is minimal (<1%) for iron, but ferric carboxymaltose complex is not dialyzable. In patients with iron deficiency, ~50-60% of administered iron is incorporated into hemoglobin and red blood cells within 2-4 weeks; the remainder is stored as ferritin and hemosiderin. The carboxymaltose moiety is partially metabolized and excreted via urine and feces.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent